The CELESTIAL-301 trial evaluating SynKIR-310, a novel CAR T-cell therapy, has dosed its first patient with relapsed/refractory B-cell non-Hodgkin lymphoma.
Sarah Cannon Research Institute
Latest Content
Recent regulatory activities suggest that the understanding of TROP2-directed therapies remains muddled.